TargetBeta
PIK3CD
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta · also p110D · Phosphatidylinositol 3-kinase family
6 programs in company-led studies act on PIK3CD, from 6 companies: 3 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (6 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| idelalisibrule | Gilead Sciences | phase 4 | 282 running | – | NCIt |
| leniolisibrule | Pharming Group | phase 3 | 94 running | – | ChEMBL |
| gedatolisibrule | Pfizer | phase 3 | 93 running | MTOR, PIK3CA, PIK3CB, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3R5 | ChEMBL |
| duvelisibrule | SecuraBio | phase 3 | 262 running | PIK3CG | ChEMBL |
| roginolisibrule | iOnctura | phase 2 | 44 running | – | the studies' text |
| paxalisibrule | Kazia Therapeutics | phase 2 | 41 running | PIK3CA, PIK3CB, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3R5 | ChEMBL |
Conditions their studies are in
- Leukemia, Lymphocytic, Chronic, B-Cell, 2 programs
- Lymphoma, Follicular, 2 programs
- Primary Myelofibrosis, 2 programs
- Breast Neoplasms, 1 program
- Carcinoma, Non-Small-Cell Lung, 1 program
- Colorectal Neoplasms, 1 program
- Common Variable Immunodeficiency, 1 program
- Endometrial Neoplasms, 1 program
- Glioblastoma, 1 program
- Hematologic Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026idelalisib · Gilead Sciences · phase 4 · NCT06736990
- Nov 30, 2026leniolisib · Pharming Group · phase 3 · NCT05438407
- Jan 2027roginolisib · iOnctura · phase 2 · NCT06879717
- Feb 2027paxalisib · Kazia Therapeutics · phase 2 · NCT07287202
- Jan 2028gedatolisib · Pfizer · phase 3 · NCT06190899
- Feb 2028duvelisib · SecuraBio · phase 3 · NCT06522737
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.